BBOT.US BridgeBio Oncology Therapeutics, Inc.
- Market cap
- USD 172M
- P/E
- 4.0x
- P/B
- 0.65x
- ROE
- -60.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BBOT.US undervalued?
Graham numberBBOT.US trades 65.9% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BridgeBio Oncology Therapeutics, Inc. fundamental analysis
No fundamental analysis for BridgeBio Oncology Therapeutics, Inc. yet.
BridgeBio Oncology Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioav…
Full company profileBridgeBio Oncology Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BridgeBio Oncology Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | - | - | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | - | -610K | - |
| Operating Income | -43.4K | -3.52K | -64.8M | -80.9M | -146M | -192M |
| EBITDA | -43.4K | -3.52K | -64.7M | -80.7M | -145M | -182M |
| Net Income | -43.4K | -3.52K | -64.7M | -74.3M | -134M | -177M |
| EPS | 0.00 | 0.00 | -3.16 | -5,756 | -4.30 | -2.21 |
| Balance Sheet | ||||||
| Total Assets | 144K | 145K | 333K | 194M | 448M | 346M |
| Total Liabilities | 163K | 166K | 396K | 5.71M | 37.3M | 52.8M |
| Shareholders' Equity | -18.4K | -21.9K | -63.6K | 189M | 411M | 293M |
| Cash & Short-term Investments | - | - | 250K | 1.70M | 425M | 194M |
| Total Debt | 37.0K | 43.1K | 70.1K | - | 2.77M | 2.38M |
| Cash Flow | ||||||
| Operating Cash Flow | - | - | -52.1M | -764K | -114M | -145M |
| Capital Expenditure | 0.00 | 0.00 | 414K | 49.0K | 606K | 112K |
| Free Cash Flow | - | - | -52.5M | -764K | -115M | -145M |
| Ratios | ||||||
| ROE | - | - | - | -39.4% | -32.6% | -60.3% |
| ROA | -30.1% | -2.4% | -19,435.3% | -38.2% | -29.9% | -51.1% |
| Debt to Equity | - | - | - | - | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
BridgeBio Oncology Therapeutics, Inc. dividends
BridgeBio Oncology Therapeutics, Inc. has not paid dividends in the last 5 fiscal years.
Who owns BridgeBio Oncology Therapeutics, Inc.
- Insiders 27.10%
- Institutions 72.90%
- Public & others 0.00%
- Shares outstanding 80.3M
- Free float 35.8M
Top funds holding BBOT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.42M | 1.77% | 0.00% | Sep 2026 |
| BlackRock Health Sciences Opps Inv A | 883K | 1.10% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 707K | 0.88% | +2.68% | Oct 2026 |
| iShares Biotechnology ETF | 373K | 0.47% | -0.19% | Oct 2026 |
| BlackRock Health Sciences Term Trust | 264K | 0.33% | 0.00% | Jun 2026 |
| Fidelity Select Biotechnology | 240K | 0.30% | 0.00% | Aug 2026 |
| Schwab US Small-Cap ETF™ | 227K | 0.28% | +0.23% | Oct 2026 |
| T. Rowe Price Health Sciences | 223K | 0.28% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 206K | 0.26% | -14.49% | Sep 2026 |
| Victory Small Cap Stock | 129K | 0.16% | -3.00% | Sep 2026 |
| Fidelity Total Market Index | 90.3K | 0.11% | -0.05% | Sep 2026 |
| Fidelity Series Total Market Index | 74.1K | 0.09% | 0.00% | Sep 2026 |
| BlackRock Health Sciences | 60.0K | 0.07% | 0.00% | Jun 2026 |
| Vanguard Balanced Index Inv | 44.4K | 0.06% | +820.81% | Sep 2026 |
| Pacific Select Health Sciences I | 43.4K | 0.05% | 0.00% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 34.9K | 0.04% | 0.00% | Oct 2026 |
| Virtus Biotech Clinical Trials ETF | 34.5K | 0.04% | 0.00% | Oct 2026 |
| Schwab Total Stock Market Index | 32.0K | 0.04% | 0.00% | Sep 2026 |
| Direxion Daily S&P Biotech Bull 3X ETF | 29.0K | 0.04% | 0.00% | Oct 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 28.8K | 0.04% | 0.00% | Sep 2026 |
Top institutions holding BBOT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Cormorant Asset Management, LLC | 17.9M | 22.30% | 0.00% | Jun 2026 |
| Deerfield Management Co | 4.89M | 6.09% | 0.00% | Jun 2026 |
| Omega Fund Management LLC | 3.29M | 4.10% | 0.00% | Jun 2026 |
| Alphabet Inc | 2.82M | 3.52% | 0.00% | Jun 2026 |
| EcoR1 Capital, LLC | 2.82M | 3.52% | 0.00% | Jun 2026 |
| Wellington Management Company LLP | 2.79M | 3.48% | -1.03% | Jun 2026 |
| Enavate Sciences GP, LLC | 2.63M | 3.28% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 2.62M | 3.27% | +3.52% | Jun 2026 |
| Novo A/S | 2.25M | 2.81% | +2.93% | Jun 2026 |
| BlackRock Inc | 2.15M | 2.69% | +3.15% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.01M | 2.50% | +272.49% | Jun 2026 |
| LAURION CAPITAL MANAGEMENT LP | 2.00M | 2.50% | +4.16% | Jun 2026 |
| Armistice Capital, LLC | 1.76M | 2.20% | +32.83% | Jun 2026 |
| State Street Corp | 1.04M | 1.29% | +358.10% | Jun 2026 |
| Aisling Capital Management LP | 1.02M | 1.27% | 0.00% | Jun 2026 |
| Opaleye Management Inc | 700K | 0.87% | +1,213.76% | Jun 2026 |
| Geode Capital Management, LLC | 622K | 0.78% | +7.44% | Jun 2026 |
| Granahan Investment Management Inc.. | 559K | 0.70% | +141.74% | Jun 2026 |
| Sphera Funds Management Ltd. | 461K | 0.58% | 0.00% | Jun 2026 |
| Adage Capital Partners Gp LLC | 400K | 0.50% | 0.00% | Jun 2026 |
BridgeBio Oncology Therapeutics, Inc. company profile
- Company name
- BridgeBio Oncology Therapeutics, Inc.
- Ticker
- BBOT.US
- Exchange
- USA Stocks
- Listed since
- Aug 12, 2025
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 88
- Fiscal year end
- December
- Address
- 256 East Grand Avenue, South San Francisco, CA, United States, 94080
- Phone
- 650 405 4770
- Website
- bbotx.com
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
BridgeBio Oncology Therapeutics, Inc. management
10- Dr. Neil Kumar Ph.D.Executive Chairman · born 1979
- Dr. Frank P. McCormick Ph.D.Co-Founder, Non-Executive Director & Chair of the Advisory Board · born 1950
- Dr. Yong Ben M.B.A., M.D.Chief Medical & Development Officer · born 1974
- Dr. Pedro J. Beltran M.D., Ph.D.Chief Executive Officer and Director · born 1971
- Mr. Marc CoboVP of Finance & Controller · born 1981
- Mr. Idan Elmelech M.A., M.B.A.Chief Operating Officer · born 1993
- Mr. Aaron Chan J.D.Vice President of Legal
- Mr. Bin Wang Ph.D.Senior Vice President of Drug Discovery
- Mr. Daniel Watson Ph.D.Senior Vice President of Chemistry, Manufacturing & Controls
- Mr. Rui Xu Ph.D.Senior Vice President of Drug Discovery